Opendata, web and dolomites

ThromboSLE

Accurate assessment of thrombosis risk in systemic lupus erythematosus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ThromboSLE project word cloud

Explore the words cloud of the ThromboSLE project. It provides you a very rough idea of what is the project "ThromboSLE" about.

viability    market    complications    morbidity    million    life    erythematosus    investing    thrombosis    thrombotic    anticoagulant    sales    accurate    disease    event    reduce    direct    commercial    reducing    innovation    interventions    profits    verification    complication    entering    substantial    specificity    caused    systemic    mortality    conduct       feasibility    benefit    events    rehabilitation    thrombosle    company    strategy    opportunity    cellular    treating    2025    threatening    160    diagnostic    sle    apart    prophylaxis    healthcare    sme    economic    highest    functional    final    risk    blood    forecasts    worldwide    good    dutch    patients    smei    plasma    lupus    lower    death    sensitivity    western    business    fail    respect    ratio    expertise    hospitals    generate    causes    opens    innovative    readiness    times    median    sciences    mechanism    cumulated    technological    group    biomarker    total    advantageous    accurately    gbs    introduction    monitoring    components    identification   

Project "ThromboSLE" data sheet

The following table provides information about the project.

Coordinator
GOOD BIOMARKER SCIENCES BV 

Organization address
address: TEIJLINGERLAAN 59
city: SASSENHEIM
postcode: 2171 CD
website: www.gbsleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://gbsleiden.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GOOD BIOMARKER SCIENCES BV NL (SASSENHEIM) coordinator 50˙000.00

Map

 Project objective

Patients with systemic lupus erythematosus (SLE) are at high risk for thrombosis, a major and life-threatening complication of SLE and one of the main causes of death in SLE. There is a need for the accurate identification of patients that are at highest risk, as in this group the risk/benefit ratio for anticoagulant prophylaxis is advantageous. As in SLE thrombosis is caused by disease-specific mechanism, current testing methods fail to accurately assess thrombosis risk in SLE. Applying its unique expertise in functional analysis of blood plasma and cellular components, the Dutch SME Good Biomarker Sciences (GBS) has developed ThromboSLE, an innovative test to assess thrombosis risk in SLE with high sensitivity and specificity. Apart from reducing morbidity and mortality from thrombosis-related complications, the introduction of ThromboSLE will reduce healthcare costs: Thrombotic events cause high healthcare costs, including direct cost for interventions and rehabilitation cost and the total median costs for prophylaxis are four times lower than those for thrombotic event management. This opens a strong business opportunity for GBS, which aims to offer the test to hospitals treating and monitoring SLE patients in Europe and worldwide. The commercial exploitation of the diagnostic product will have substantial impact on GBS with respect to company growth and business strategy. With 160,000 SLE patients in the target market Western Europe, GBS forecasts to generate cumulated profits of €6.6 million from ThromboSLE sales by 2025. Before entering and investing into the innovation project (SMEi phase II) and to reach market readiness for ThromboSLE, GBS aims to conduct a feasibility study (SMEi phase I) for final verification of the technological as well as economic viability of the product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THROMBOSLE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THROMBOSLE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More